Clinical trials: Acute Depression
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder…
- Trial name
- AVENUE (NCT07227454)
- Testing
- Esketamine, Midazolam
- Where
- 49 sites in United States, Brazil and 5 more
- Volunteers
- 258 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder (Per DSM-V Criteria, Mild-to-moderate), Acute Coronary Syndrome (ACS)
Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation on Alleviating Major Depressive Disorder in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention:A Prospective, Double-Blind,Randomized Controlled Study
This is a randomized, controlled study. ACS follow- up patients aged 18 to 80 years old with hemodynamic stability, who are 14 days to 1 year after PCI, are screened through the HAMD score and the HAMA score.
- Conditions
- Depressive Disorder (Per DSM-V Criteria, Mild-to-moderate), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), Depressive Disorder
- Trial name
- NCT07454070
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Intervention
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jing Han
Depressive Disorder, Post-Acute COVID-19 Syndrome
IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition
This is a monocentric, randomized pilot study conducted at the Max Planck Institute of Psychiatry, Munich. The study investigates the effects of two different intermittent theta-burst stimulation (iTBS) schedules on biological…
- Trial name
- IMPACT-D+ (NCT07197138)
- Testing
- Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMS
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Perimenopausal Depression, Post Menopausal
The Effects of Estrogen Withdrawal on Mood Symptoms in Women
This study evaluates the effects on mood when stopping estrogen replacement therapy. The purpose of this study is to investigate the effects of estrogen levels on perimenopausal depression.
- Conditions
- Perimenopausal Depression, Post Menopausal, Healthy, Depression
- Trial name
- NCT00060736
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression, Acute Ischemic Stroke
Prophylactic Effects of Agomelatine for Poststroke Depression
The incidence of depression in stroke patients with frontal lobe involvement was reported to be as high as 42%. Agomelatin, a type 1/2 melatonin receptor agonist and serotonin 2C receptor antagonist, is effective in treatment of…
- Trial name
- PRAISED (NCT05426304)
- Testing
- Agomelatine
- Volunteers
- 420 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Major Depressive Disorder
Evaluation of the H-coil Transcranial Magnetic Stimulation TMS Device - Safety and Feasibility Study for Acute and Maintenance Treatment in Major Depressive Episode
This is a prospective open label study of acute and maintenance treatment of MDD. The acute phase consists of daily treatments for 4 weeks.
- Trial name
- NCT00807105
- Testing
- H-coil dTMS
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Shalvata Mental Health Center
Depression in Remission
Prucalopride and Cognition in Recovered Depression
The current study has two aims: 1. To test the effect of 5-HT4 receptor agonism on cognition (including memory, attention and cognitive control) in individuals with previous history of depression. 2.
- Trial name
- PROGRESS (NCT05220228)
- Testing
- Prucalopride
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Cerebral Stroke
Links Between Depression, Anxiety, Coping and Quality of Life After a Stroke
Introduction and literature review With 130 000 cases per year in France in 2010, stroke is one of the most common neurological diseases, often leaving many disabling sequelae physical and cognitive levels (currently live 500 000…
- Trial name
- COPING (NCT02778334)
- Testing
- survey
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Bipolar Disorder, Bipolar Depression
Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up
This study aims to study prospectively for 8 months a sample of bipolar patients with acute depressive episode in order to identify that factors associated with functional impairment, with especial attention to the presence of…
- Trial name
- NCT01255982
- Where
- 24 sites in Spain
- Volunteers
- 249 people
- Sponsor
- AstraZeneca
Acute Leukemia, Recurrent Leukemia
Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients
This trial investigates how well bright white light therapy works in improving sleep, fatigue, distress, depression, and anxiety, side effects that are often experienced during an intense leukemia treatment regimen, in…
- Conditions
- Acute Leukemia, Recurrent Leukemia, Refractory Leukemia
- Trial name
- NCT04597086
- Testing
- Best Practice, Bright White Light Therapy, Survey Administration
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Angina Pectoris, Acute Coronary Syndrome
Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19
Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure…
- Conditions
- Angina Pectoris, Acute Coronary Syndrome, Coronary Syndrome, Coronary Artery Disease
- Trial name
- eCardioCovid19 (NCT04325867)
- Testing
- Tele-medicine platform
- Where
- 2 sites in Romania
- Volunteers
- 200 people
- Sponsor
- Professor Adrian Covic
Sleep Initiation and Maintenance Disorders, Depression
STILDEP: Zolpidem in Depressive and Dysthimic Patients
Primary objective: To show that the combination of Zolpidem + antidepressant therapy is more effective in the treatment of the secondary insomnia of depressive and dysthimic patients than antidepressant therapy alone in the acute…
- Trial name
- NCT00292734
- Testing
- Zolpidem
- Where
- Hungary
- Volunteers
- 120 people
- Sponsor
- Sanofi
Acute Coronary Syndrome, Depression
The Impact of Depression and/or Anxiety on PCI Patients
The purpose of this study is to evaluate how depression and/or anxiety could effect the prognosis of the patients post-ACS after PCI.
- Conditions
- Acute Coronary Syndrome, Depression, Anxiety
- Trial name
- NCT03057691
- Testing
- antidepressive and anti-anxiety therapy
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Depression, Suicidal Ideation
Emergency Ketamine Treatment of Suicidal Ideation
The objective of the current program of research will be to test whether intranasal ketamine treatment is more effective than placebo in reducing suicidal ideation in suicidal patients presenting for acute treatment in emergency…
- Conditions
- Depression, Suicidal Ideation, Suicidal Impulses
- Trial name
- NCT02183272
- Testing
- Intranasal Ketamine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Cincinnati
Healthy Volunteer, Major Depressive Disorder
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect.
- Conditions
- Healthy Volunteer, Major Depressive Disorder, Depression
- Trial name
- NCT03065335
- Testing
- Ketamine, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Prediction of the Response to a Course of Transcranial Magnetic Stimulation (rTMS) Based on Heart Rate Variability
Changes in heart rate variability following a single session of rTMS will be tested as a predictor of response to a course of 30 rTMS sessions in patients with major depressive disorder (MDD).
- Trial name
- DEP&MOD (NCT06451809)
- Testing
- repetitive transcranial magnetic stimulation
- Where
- 9 sites in France
- Volunteers
- 160 people
- Sponsor
- GCS CIPS
Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)
Brimonidine 0.33% for Rosacea-Related Facial Erythema
This study looks at whether a topical gel called 0.33% brimonidine can reduce persistent facial redness caused by rosacea. The study was carried out in two parts.
- Trial name
- NCT07431476
- Testing
- Brimonidine 0.33% gel
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Istanbul Training and Research Hospital
Recruitment
Finding a Biomarker for Acute Neuromodulation Effects in Adolescent Depression
This pilot study aims to examine the feasibility of recruiting depressed adolescents to examine changes in emotional processing and in neural responses to emotional stimuli after one session of rTMS (which is followed by an…
- Trial name
- NCT05832294
- Testing
- Treatment rTMS
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Post-Acute COVID-19 Syndrome, Biofeedback, Psychology
Prevention of Long Covid Syndrome
Biofeedback equipment is classified by the Food and Drug Administration (FDA) as medical device class II and this type of equipment/treatment has shown evidence regarding stress management in post-Covid-19 syndrome.
- Conditions
- Post-Acute COVID-19 Syndrome, Biofeedback, Psychology, Quality of Life, Depressive Symptoms
- Trial name
- NCT05793736
- Testing
- Biofeedback training, Treatment as usual
- Where
- Italy
- Volunteers
- 17 people
- Sponsor
- University of Cagliari